Physicians' Experiences as Patients with Statin Side Effects: A Case Series. by Koslik, Hayley J et al.
UC San Diego
UC San Diego Previously Published Works
Title
Physicians' Experiences as Patients with Statin Side Effects: A Case Series.
Permalink
https://escholarship.org/uc/item/67w156cq
Journal
Drug safety - case reports, 4(1)
ISSN
2199-1162
Authors
Koslik, Hayley J
Meskimen, Athena Hathaway
Golomb, Beatrice Alexandra
Publication Date
2017-12-01
DOI
10.1007/s40800-017-0045-0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
CASE SERIES
Physicians’ Experiences as Patients with Statin Side Effects:
A Case Series
Hayley J. Koslik1 • Athena Hathaway Meskimen1 • Beatrice Alexandra Golomb1
Published online: 20 February 2017
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract Physicians are among those prescribed statins
and therefore, subject to potential statin adverse effects
(AEs). There is little information on the impact of statin
AEs on physicians affected by them. We sought to assess
the character and impact of statin AEs occurring in
physicians and retired physicians, and to ascertain whether/
how personal experience of AEs moderated physicians’
attitude toward statin use. Seven active or retired physi-
cians from the United States communicated with the Statin
Effects Study group regarding their personal experience of
statin AEs. AE characteristics, experience with (their own)
physicians, and impact of AE was ascertained. We inquired
whether or how their experience altered their own attitude
toward statins or statin AEs. Patient A: Atorvastatin 40
then 80 mg was followed by cognitive problems, neu-
ropathy, and glucose intolerance in a Radiologist in his 50s
(Naranjo criteria: probable causality). Patient B: Atorvas-
tatin 10 mg was followed in 2 months by muscle weakness
and myalgia in an Internist in his 40s (probable causality).
Patient C: Atorvastatin, ezetimibe/simvastatin, rosuvastatin
at varying doses was followed shortly after by irritability,
myalgia, and fatigue in a Cardiac Surgeon in his 40s
(probable causality). Patient D: Simvastatin 20 then 40 mg
was followed in 4 years by mitochondriopathy, myopathy,
neuropathy, and exercise intolerance in an Emergency
Medicine physician in his 50s (definite causality). Patient
E: Simvastatin 20 mg and niacin 1000 mg was followed in
one month by muscle weakness and myalgia in a Physical
Medicine and Rehabilitation physician in his 50s (probable
causality). Patient F: Lovastatin 20 mg then simvastatin
20 mg, atorvastatin 20 mg, rosuvastatin 5 mg, niacin
20 mg and ezetimbe 10 mg was followed by muscle
weakness and myalgia in an Obstetrician/Gynecologist in
his 70s (definite causality). Patient G: Ezetimibe/simvas-
tatin and atorvastatin (dose unavailable) was followed
shortly after by cognitive problems in a Radiologist in her
80s (probable causality). Thus AEs affected multiple
quality-of-life relevant domains, often in combination,
encompassing muscle (N = 5), fatigue (N = 2), peripheral
neuropathy (N = 2), cognitive (N = 2), dysglycemia
(N = 1) and behavioral manifestations (N = 1). In five, the
AEs affected the physician professionally. Five physicians
experienced dismissive attitudes in some of their own
healthcare encounters. One noted that his experience
helped not only his own attention to statin AEs, but that of
other physicians in his community. Several stated that their
experience altered their understanding of and/or attitude
toward statin AEs, and/or their view of settings in which
statin use is warranted. Statin AEs can have profound
impact in high functioning professionals with implications
to the individual, their professional life, and those whom
they serve professionally.
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Key Points
This is the first analysis to address the experience of
physicians themselves affected by adverse effects
(AEs) of statin medications, encompassing muscle,
neuropathic, cognitive, and behavioral AEs.
The impact of statin AEs in physicians can be
profound, professionally and personally, in some
cases requiring major professional modification or
early retirement.
Poor awareness of statin problems by medical
providers, and low receptiveness to reports of such
problems, can extend even to patients when they
themselves are physicians.
Introduction
Statins (HMG-CoA reductase inhibitors) are among the
best-selling prescription drugs and have been viewed as
having a favorable safety profile, but like all drugs, they
bear potential side effects. While adverse effects (AEs) are
reported to be rare in clinical trials, they are less uncom-
mon in clinical experience [1, 2]. It has been observed that
physicians often dismiss the possibility of statin-related
etiology when patients present with side effects linked to
statin use [3], and that patients with statin AEs commonly
perceive that their physicians do not appreciate the quality-
of-life impact of their AE [4].
Physicians, current and retired, are among those who
take statins. There are two reasons for our interest in statin
AEs in physicians. First, consideration of AE impact has
focused primarily on direct health ramifications and has not
investigated professional consequences to the individual.
Properly contextualizing the impact of statin AEs requires
attention to this additional dimension. Second, patients
with statin AEs have communicated instances in which
their physician became more receptive to the possibility of
statin AEs when the physicians themselves or their per-
sonal family or professional contacts developed statin AEs.
We were interested in the issue of whether experiencing a
statin AE altered physicians’ own attitudes regarding statin
AEs reported by others.
We present seven cases of statin AEs in physicians.
Method
The Statin Effects Study is a patient-targeted statin AE
reporting effort approved by the University of California,
San Diego Human Research Protections Program (HRPP).
Materials were reviewed to identify individuals who had
communicated with the study group and noted that they
were physicians. Fourteen physicians who had reported
statin AEs were identified. Ten qualifying individuals
provided informed consent and completed a self- or inter-
viewer-administered HRPP-approved survey, which eli-
cited information on subject characteristics including risk
factors for statin AEs [5], statin usage, adverse effect fea-
tures, professional impact, adherence to Naranjo criteria,
and the subject’s experience within the medical commu-
nity. Using the Naranjo Adverse Drug Reaction (ADR)
probability scale, cases were coded as meeting criteria for
doubtful, possible, probable or definite presumptive statin
AE causality. Three cases lacked a trial off statins, fol-
lowed by improvement, limiting the causality determina-
tion to at most ‘‘possible’’; these cases were therefore
excluded, providing seven cases that are presented.
For brevity, two cases are highlighted in the text, with
five additional cases detailed in a table. For purposes of
exposition, cases have been assigned arbitrary, alphabeti-
cally-ordered, letter labels (unconnected to subject names).
Results
Dr. A, a radiologist in his 50s, stated that he developed
marked cognitive problems and also neuropathy shortly
after increasing his atorvastatin dose from 40 to 80 mg/day.
Effects were new, marked, sustained, and interfered with
his work, leading to difficulty understanding case presen-
tations, to radiology reading errors (including right/left
errors on readings), and to placement of orders for the
wrong patients. These consequences to his professional
accuracy led him to fear medicolegal repercussions. He did
not share his cognitive concerns with his own physician,
leery of risks and ramifications from such disclosure.
However, he did share the neuropathy symptoms. His
physician, whom Dr. A noted bore a ‘‘Top Doctor’’ des-
ignation, stated that no further assessment was warranted
for neuropathy symptoms except in diabetics. No sugges-
tion was made by his doctor of a possible statin role, or
suggestion for a trial of statin discontinuation, until a
medical student commented on the association of neu-
ropathy to statin use. Discontinuation of statins, after
3 years of sustained symptoms, led to rapid and striking
improvement in cognitive function. By a week after dis-
continuation, Dr. A noted dramatic cognitive recovery,
which he perceived to be approximately complete. He
observed more gradual recovery of neuropathy symptoms,
which he characterized as having improved by an estimated
95% at 8 months (improvement having apparently pla-
teaued at that level).
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Dr. B is an internist in his 40s who reported that,
6 weeks after commencing statins, he developed rapidly
progressing muscle symptoms comprising fatigue, pain,
weakness and shortness of breath. Numerous specialist
referrals occurred and tests were conducted, and concerns
regarding possible amyotrophic lateral sclerosis (ALS)
were expressed. Ultimately a muscle biopsy showed
mitochondrial myopathy that was attributed in the biopsy
pathology report to statin use (compatible literature is
available [5–7]). Statin discontinuation was undertaken
after only *2 months of statin use, and although what had
been a rapid progression of symptoms fully arrested,
according to the patient, recovery was limited and remains
partial, 13 years later. Professional impact of his statin-
related problems was marked: he discontinued inpatient
care, call, and curtailed his hours, patient volume, and pay,
also refitting his offices with higher desks and chairs to
enable him to slide off chairs to rise.
Medical specialty, age at symptom onset, sex, statin,
dose, risk factors, adverse effect, and Naranjo Causality
score for these two and five additional physician cases are
presented in Table 1. Information on the five additional
affected physicians, with further cognitive, muscle, neu-
ropathic, and adding behavioral AEs, are provided in
Table 2 with brief details on the AEs, interaction with
physician, referrals/tests/diagnoses, effect on attitude as a
physician, as well as professional impact (where relevant).
These cases illustrate key points. AEs of statins include
muscle [4], cognitive [8], neuropathy [9], and behavioral
symptoms [10] (among others) and physicians and retired
Table 1 Synopsis of physician cases
Case Medical
specialty
Age at
symptom
onset
Sex Statin Dose
(mg)
Risk factors Adverse effect Naranjo
causality
Dr.
A
Radiology 50s M Atorvastatin 40,80 High dosea Cognitive 6
ProbableNeuropathy
Glucose
intolerance
Dr.
B
Internal
medicine
40s M Atorvastatin 10 c Muscle weakness 5
ProbableMyalgia
Dr.
C
Cardiac surgery 40s M Atorvastatin 20, 40 High dosea; combination with other
lipid lowering agent
Irritability 7
ProbableMyalgia
FatigueEzetimibe/
Simvastatin
10/40
Rosuvastatin 20, 40
Dr.
D
Emergency
Medicine
50s (start
statins)
M Simvastatin 20, 40 Familial risk, high dosea Mitochondriopathy 9 Definite
Myopathy
60s (max
symptoms)
Neuropathy
Exercise
intolerance
Dr.
E
Physical
medicine and
rehab
50s M Simvastatin 20 Active athlete; combination with
other lipid lowering agent
Muscle weakness 5
ProbableMyalgiaNiacin 1500
Dr.
F
OB/Gyn 70s M Lovastatin 20 Diabetes Muscle weakness 9 Definite
MyalgiaSimvastatin 20
Atorvastatin 20
Rosuvastatin 5
Niacin 20
Ezetimibe 10
Dr.
G
Radiology 80s F Ezetimibe/
simvastatin
Atorvastatin
c Age, female, PADb Cognitive 7
Probablec
M male, F female, OB/Gyn obstetrics and gynecology, PAD peripheral arterial disease
a High dose defined as the potency equivalent of simvastatin 40 mg or higher
b Linked to oxidative stress, mitochondrial dysfunction, and all Metabolic Syndrome factors, which in turn are risk factors
c Not known
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Table 2 Further information on the five additional cases
Dr. C
Irritability
Muscle pain
Fatigue
(1) Following initiation of statins, Dr. C developed fatigue and muscle pain. New development of irritability/short temper
toward coworkers, though not noted by Dr. C., was noted by coworkers, leading to professional action/referral. Statin
discontinuation led to resolution of fatigue/muscle symptoms (judged by Dr. C) and irritability (judged by coworkers)
(2) At Dr. C’s suggestion of a possible statin link, Dr. C’s physician acknowledged that he had heard of side effects with
rosuvastatin at the 40 mg dose. At Dr. C’s request, the psychiatrist to whom his employer referred Dr. C communicated
with physician investigators familiar with behavioral changes as a manifestation of statin AEs, who advised that the
behavioral manifestations could represent a statin AE, with likelihood of a statin foundation augmented by concurrent
development of fatigue and muscle symptoms. On this basis the statin was discontinued
(3) Dr. C’s employer referred him for psychiatric evaluation because of behavioral problems at work
(4) Dr. C. previously held statins in favorable opinion, he now says, ‘‘I have no interest in going back on statins.’’ He
reports awareness that statins can lead to behavioral changes, and deems more education on statin AEs is needed
(5) Professional review, psychiatric evaluation
Dr. D
Mitochondriopathy
Myopathy
Fatigue
Exercise
intolerance
(1) Dr. D. experienced a clear decline in exercise tolerance that progressed over a 4 year period on statins, with
development and progression of myalgias ultimately rated 8–9/10 in severity, and extreme lethargy. Discontinuation of
statins led to gradual improvement in muscle pain: 3.5 years after statin discontinuation, he reports 75% improvement in
myalgias, however, there has been no discernible improvement in exercise intolerance
(2) Dr. D’s non-physician sister proposed the statin connection after she herself suffered intolerance. Dr. D’s physicians
were generally dismissive of a statin connection. Dr. D describes a ‘‘pervasive skepticism’’ at the idea, with physicians
‘‘rolling their eyes’’ at the suggestion, even when he presented them with literature supporting the relationship
(3) Referrals were made to cardiology, rheumatology, and neurology. Testing encompassed blood tests, MRI brain and
spine, multiple cardiac catheterizations, EMG/NCS, and ultimately a muscle biopsy with mitochondrial testing. The NCS
identified conduction problems of unclear etiology. The biopsy report read ‘‘reproducible abnormalities were found most
prominently in complexes II-III (succinate cytochrome C reductase) and complex IV (cytochrome C oxidase) with
reductions to 12 and 18% of their respective normal means. This patient is considered to have statin-induced myopathy’’
(4) Dr. D. described his own prior attitude toward statins as ‘‘elementary and naı¨ve, that they were bad in some people, but
that there would be clear manifestations and happen quickly within weeks. I thought a normal CK would essentially rule
it out, that the symptoms were largely reversible.’’ He now emphasizes that the side effects ‘‘can be very disabling, can
happen in substantially delayed fashion, the CK can be normal’’
(5) Disability from statin AEs contributed to retirement
Dr. E
Muscle weakness
Muscle pain
(1) Dr. E tolerated simvastatin for 13 years, however after a 2 year trial off, he resumed simvastatin with niacin. He retired
early to pursue athletic adventures, but a month after recommencing statin and niacin, developed new exercise
intolerance, rapid muscle fatigue, and loss of muscle strength. He discontinued the statin a month later. Two years later,
although notable improvement has occurred, there remains a significant residuum
(2) Dr. E’s experience with the healthcare system was unfavorable. He felt his doctors were unsympathetic, and that his
symptoms ‘‘did not register much concern’’ from them
(3) Neurological evaluation with NCS/EMG showed atypical proximal muscle unit abnormalities, slowed nerve
conduction, and fasciculations. Brain and spinal MRI were negative. He also saw a urologist for low testosterone
(simvastatin has been shown to reduce testosterone [27, 28]), but a 4 month trial of testosterone replacement did not
confer benefit
(4) Dr. E’s perspective following this experience is that ‘‘statins should not be prescribed to those who are athletically
inclined.’’ He observes that they have ‘‘a very real propensity to adversely impact the mitochondria on a permanent basis’’
(5) N/A, already retired
Dr. F
Muscle weakness
Muscle pain
(1) Dr. F developed muscle pain and weakness (to the point where he could no longer drive) with each of a succession of
lipid lowering medications (most statins), with improvement when these were discontinued. However, an extensive
cardiac history caused trials off statins to be short-lived. For instance, atorvastatin was stopped in 2000 when his
weakness became severe, and improvement in walking was noted 2 months later, but rosuvastatin was prescribed due to
elevated cholesterol levels, resulting in a rapid return of weakness
(2) Dr. F’s interaction with the medical system was relatively positive. Although his cardiologist initially dismissed the
possible connection of statins to his weakness, when the cardiologist’s own family member developed similar statin AEs,
he began to investigate the relationship
(3) Dr. F. was referred to neurology and endocrinology, had blood tests, NCS/EMG, and muscle biopsy. He received
successive diagnoses of arthritis, diabetic neuropathy, depression, and normal aging. His muscle biopsy showed changes
consistent with mitochondrial myopathy on histology (based on ragged red fibers and Cox staining), without confirmatory
evidence on electron microscopy
(4) Prior to his own experience, Dr. F. had no strong opinions about statins. He felt they were mostly safe and certainly
indicated for people with cardiovascular disease. Now, whenever he and his wife (also a physician) notice gait
abnormalities in their friends and even strangers, they inquire whether or not they are on statins
(5) N/A, already in the process of retiring
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physicians are not exempt from risk. AE cases reported
here have evidence for at least probable statin causality
[11]. Career implications of statin problems can arise from
cognitive and muscle problems, as in the two cases above,
as well as from behavioral AEs of statins (Case C in
Table 2). Each have potential for impact to physicians’
career, and some AEs, perhaps particularly cognitive and
behavioral AEs, have potential for ramifications to patients.
(We did not elicit, and participants did not volunteer,
instances—if any—in which such ramifications were real-
ized.) Physicians seen by individuals affected by statin AEs
(including physicians seen by physicians reporting such
AEs) were commonly unfamiliar with these statin AEs, and
for five of the cases, some of the physicians consulted were
initially dismissive [3].
Many participants experienced professional impact. In
neither cases of Dr. A nor Dr. B did the physicians caring
for the statin-affected physician-patients have an under-
standing of the potential causal role of statins initially. Dr.
A was informed of the possible connection of statins to
neuropathy not by his physician, but by a medical student
working with his physician, who was aware of the reported
association. Dr. B’s statin experience occasioned the pos-
itive development of increased awareness of statin adverse
effects—and vigilance for them—both in himself (though
still affected, he has retained a primary care practice) and
among other physicians in his community. Finally, both
physicians saw arrest of progression, and symptom
improvement after discontinuing the statin, however nei-
ther returned fully to their previous health states [7, 12].
(Dr. A states that he retains some residual neuropathy,
though it has markedly abated.) We emphasize that for
each of the reported symptoms, recovery profiles (in time
course and completeness) vary across affected individuals;
the swift reported recovery of cognitive function reported
by Dr. A is on the rapid end of the recovery-time course
spectrum.
Discussion
To our knowledge, this is the first report to address statin
AEs in physicians and to evaluate how experiencing a
statin AE affected physicians professionally, how knowl-
edgeable and receptive these physicians find other profes-
sionals to be in professional encounters, and whether and
how experiencing statin-associated problems influenced
their own (and if known, other physicians’) attitudes
towards statin AEs. These cases underscore that commonly
reported statin AEs—here encompassing muscle [4], cog-
nitive [8], fatigue [13], neuropathic [9], and behavioral
[10]—also afflict high functioning professionals such as
physicians, in whom these symptoms can have profound
professional implications, contributing in some to early
retirement (Table 2) or persistent disability. These cases
reprise a number of observations from other settings.
Symptom onset can be delayed [4, 8]. Older age is a risk
factor for statin AEs [5, 14, 15], and people continue to age
while taking statins—moreover, physiological aging may
be accelerated by the processes that underlie statin AEs [5].
Higher dose increases risk (Drs. A, C, D) [5]. For those
who remain on statins after the first symptom arises,
emergence of symptoms spanning several categories is not
uncommon, likely reflecting common pathophysiological
foundations [5]. Rarely, symptoms may initially worsen
with discontinuation. (We note this is consistent with evi-
dence that antioxidant effects can arise (and reverse)
quickly, prior to lipid effects [16]; while some prooxidant
effects, linked for instance to recovery of lipid transport of
antioxidants, may take longer to reverse. This may, in
some, engender an initial worsening of statin-induced
prooxidant-antioxidant balance, on statin discontinuation.)
Resolution of AEs can be incomplete (whether by patient
report or objective testing) [6, 7] and residual disability
may be profound [4, 17]. Statin AEs, including muscle
wasting, weakness, and exercise intolerance as well as
Table 2 continued
Dr. G
Cognitive
problems
(1) Shortly after statin initiation, Dr. G developed confusion, disorientation, and short-term memory loss. She asked
repetitive questions and had a short attention span. Statins were discontinued, followed by marked improvement in
cognitive function. A month after discontinuation, she recalled running into one of her former colleagues in the grocery
store and being able to immediately recognize the person (a clear improvement over her prior state). This acquaintance
exclaimed that she looked much better than 8 months previously, when they had last interacted
(2) Dr. G’s physician dismissed the potential statin connection. Her son stated, ‘‘He replied in a condescending tone of
disbelief that I ‘read too much’’’
(3) Dr. G. was referred to a neurologist, and treated with donepezil for a year under the assumption the cognitive problems
may be Alzheimer’s. Other diagnoses that had been considered included depression and pseudo-dementia
(4) Not known
(5) Disability from statin AEs contributed to retirement
(1) Statin AE synopsis; (2): Interaction with Physician; (3): Referrals/Tests/Diagnoses; (4): Effect on Attitude as a Physician; (5): Professional
Impact
AE adverse effect, CK creatine kinase, EMG electromyography, NCS nerve conduction study, MRI magnetic resonance imaging
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neuropathy perhaps in particular [18] (but also cognitive
dysfunction) may fail to fully resolve clinically [19, 20]
and pathologically [7]. (Indeed, there may be failure of full
resolution pathologically even when there is apparent
clinical resolution [19].) Persistent muscle problems can
reflect mitochondrial myopathy [5–7]. Regarding cases in
Table 2: Behavioral symptoms may be recognized by
others rather than the individual in whom they occur (Dr.
C) [21, 22]. Athletes may be at special risk for statin
muscle problems (Dr. E) [23, 24]. Physicians seeing those
who experience statin AEs may be dismissive of symptoms
or of a possible statin connection—even, we find here,
when reported by physicians-as-patients [3].
In addition to reprising previous findings regarding the
symptoms themselves, these cases offer new insights into
impact. Professional impact in these cases varied depend-
ing on the nature and severity of the AEs—and the prox-
imity to planned retirement—from no professional effect to
early retirement to significant curtailment of hours and
income, professional review, and fears about patient con-
sequences and medicolegal action. Costs for evaluations
and referrals may be high. Some physicians, on whom
patients (including other physicians) rely for compassion
and care, may fail to take statin-related problems seriously
and may fail to follow-up on possible statin associations of
symptoms, while other physicians are receptive, and
responsive, to experiences and concerns of their patients.
Patients may not reveal cognitive symptoms to their
physicians fearing repercussions of disclosure. This may
lead to delays in addressing the cause, which can increase
prospects for repercussions to the patients whom the
physician serves. Physicians reported that their experience
altered their attitudes toward statins, reflecting awareness
of potential for symptoms, but also increased appreciation
of the impact such symptoms can have. Each of the AEs
described here has been documented in the literature in
association with statins; discussion of potential mecha-
nisms of these statin AEs can be viewed in other sources
[5–7].
As in other case series and AE surveillance approaches,
there is no defined base population or control group, so
relative rates and risk-ratios cannot be calculated. How-
ever, rates and risk-ratios are not the goal. Since the pur-
pose is to characterize and understand these AEs and their
potential impact, only subjects who have experienced an
AE are relevant. Like all studies with volunteer subjects,
there is self-selection, which may affect generalizability;
however AE reports are in any case about illustrating
potential effects, not normative ones. Subjects with mild
symptoms may not feel motivated to share their experi-
ences; those with extremely severe symptoms may be
unable to do so. Regarding the most severe problems, there
is the additional limitation that statin AEs can seldom
qualify as meeting presumptive criteria for probable or
definite AE causality if there was no improvement after
drug discontinuation. Thus, people who continue on statins
with symptoms or those in whom a progressive or irre-
versible problem may have been triggered are excluded
from consideration. Self-reported data may be influenced
by recall and reporting bias, but this shortcoming affects all
questionnaire studies. Most importantly, even if the find-
ings reported here apply only to a subset, they remain
important for that subset. Prior studies have shown that
patient AE self-reporting can be a reliable, valuable tool
[25, 26]. Additionally, Naranjo presumptive causality cri-
teria provide an independent form of causality estimate,
and the seven cases presented met literature-based criteria
for definite or probable AE causality. Physicians’ experi-
ence of statin AEs is among a suite of factors that could
influence approaches to statin prescribing; whether or how
these experiences influenced prescribing, in practitioners
who prescribed statins, was not assessed.
Conclusion
This case series, with its focus on physicians, underscores
the quality-of-life and professional impact that can attend
statin AEs, and reinforces the understanding that conse-
quences can be persistent. Greater awareness of these
problems, and greater compassion when patients present
with these conditions may be merited. Lessons drawn from
these physicians-as-patients have relevance to other pro-
fessions. (For instance, delay in addressing the cause of
cognitive compromise may have repercussions for those
served by the professional, not only for doctors but for
pilots, drivers, lawyers, nuclear facility workers,
drug/chemical/vehicle production personnel, and many
other professionals.) Care should be taken in management
decisions in relation to statin use to limit unnecessary
occurrence of AEs, and to recognize and mitigate the
impact of such AEs when they occur.
Acknowledgements We gratefully acknowledge the time and effort
of the participants who shared their information; and thank all those
who assisted with the Statin Effects Study. HJK, AHM, and BAG had
full access to all the data in the study and can take responsibility for
the integrity of the data and the accuracy of the data analysis.
Compliance with Ethical Standards
Funding This study was made possible by a donation from Dr.
Murray Rosenthal. The study funder had no role in study design; in
the collection, analysis, and interpretation of data; in the writing of
the report; and in the decision to submit the article for publication.
Conflicts of interest Hayley J. Koslik, Athena Hathaway Meskimen,
and Beatrice Alexandra Golomb have no conflicts of interest that are
directly relevant to the content of this study.
3 Page 6 of 7 H. J. Koslik et al.
Patient consent Written, informed consent was obtained from each
participant for inclusion of their case in this case series.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects.
N Z Med J. 1991;104:493–5.
2. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to
moderate muscular symptoms with high-dosage statin therapy in
hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs
Ther. 2005;19:403–14.
3. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician
response to patient reports of adverse drug effects: implications
for patient-targeted adverse effect surveillance. Drug Saf.
2007;30:669–75.
4. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associ-
ated muscle-related adverse effects: a case series of 354 patients.
Pharmacotherapy. 2010;30:541–53.
5. Golomb BA, Evans MA. Statin adverse effects: a review of the
literature and evidence for a mitochondrial mechanism. Am J
Cardiovasc Drugs. 2008;8:373–418.
6. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura
BJ, et al. Statin-associated myopathy with normal creatine kinase
levels. Ann Intern Med. 2002;137:581–5.
7. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier
WL, Barboi AC, et al. Genetic risk factors associated with lipid-
lowering drug-induced myopathies. Muscle Nerve.
2006;34:153–62.
8. Evans MA, Golomb BA. Statin-associated adverse cognitive
effects: survey results from 171 patients. Pharmacotherapy.
2009;29:800–11.
9. Gaist D, Jeppesen M, Andersen LA, Garcia Rodriguez J, Hallas J,
Sindrup SH. Statins and risk of polyneuropathy: a case-control
study. Neurology. 2002;58:1333–7.
10. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated
with statin cholesterol-lowering drugs. QJM. 2004;97:229–35.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA,
et al. A method for estimating the probability of adverse drug
reactions. Clin Pharmacol Ther. 1981;30:239–45.
12. Phillips PS, Haas RH. Observations from a statin myopathy
clinic. Arch Intern Med. 2006;166:1232–3.
13. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of
statins on energy and fatigue with exertion: results from a ran-
domized controlled trial. Arch Intern Med. 2012;172:1180–2.
14. Golomb BA, Koperski S. Who becomes weak on statins? Effect
modification exposed in a RCT by risk factor compounding.
Circulation. 2013;127:AP072.
15. Golomb BA, Koperski S, White HL. Statins Raise Glucose
Preferentially among Men who are Older and at Greater Meta-
bolic Risk. Epidemiology and Prevention; Nutrition, Physical
Activity and Metabolism 2012 Scientific Sessions; March 13–16,
2012; San Diego, CA.
16. Karatzis E, Lekakis J, Papamichael C, Andreadou I, Cimponeriu
A, Aznaouridis K, et al. Rapid effect of pravastatin on endothelial
function and lipid peroxidation in unstable angina. Int J Cardiol.
2005;101:65–70.
17. Dobkin BH. Underappreciated statin-induced myopathic weakness
causes disability. Neurorehabil Neural Repair. 2005;19:259–63.
18. Adverse Drug Reactions Advisory Committee (ADRAC). Statins
and peripheral neuropathy. Aust Advers Drug React Bull.
2005;24:6.
19. Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP.
Peripheral neuropathy associated with simvastatin. J Neurol
Neurosurg Psychiatry. 1995;58:625–8.
20. Jeppesen U, Gaist D, Smith T, Sindrup SH. Statins and peripheral
neuropathy. Eur J Clin Pharmacol. 1999;54:835–8.
21. Reilly D, Cham S, Golomb BA. First degree relatives with
behavioural adverse effects on statins. BMJ Case Rep. 2011.
doi:10.1136/bcr.09.2011.4758.
22. Cham S, Koslik HJ, Golomb BA. Mood, personality, and behavior
changes during treatment with statins: a case series. Drug Saf Case
Rep. 2015;3:1–13. doi:10.1007/s40800-015-0024-2.
23. Sinzinger H, O’Grady J. Professional athletes suffering from
familial hypercholesterolaemia rarely tolerate statin treatment
because of muscular problems. Br J Clin Pharmacol.
2004;57:525–8.
24. Golomb BA. Statins and activity: proceed with caution. JAMA
Intern Med. 2014;174:1270–2. doi:10.1001/jamainternmed.2013.
14543.
25. Fisher S, Bryant SG. Postmarketing surveillance of adverse drug
reactions: patient self-monitoring. J Am Board Fam Pract.
1992;5:17–25.
26. Fisher S, Bryant SG, Kent TA, Davis JE. Patient drug attributions
and postmarketing surveillance. Pharmacotherapy. 1994;14:202–9.
27. Golomb BA, Koperski S. Testosterone change relates to lipid
change on statins. Circulation. 2013;127:17.
28. Hyyppa MT, Kronholm E, Virtanen A, Leino A, Jula A. Does
simvastatin affect mood and steroid hormone levels in hyperc-
holesterolemic men? A randomized double-blind trial. Psy-
choneuroendocrinology. 2003;28:181–94.
Statin AEs in MDs Page 7 of 7 3
